The therapeutic potential of novel kappa opioid receptor-based treatments.

  title={The therapeutic potential of novel kappa opioid receptor-based treatments.},
  author={Sebastiano Mercadante and Patrizia Romualdi},
  journal={Current medicinal chemistry},
INTRODUCTION Similarly to the µ opioid receptor, kappa opioid receptor (KOR), is present either in the central nervous system and peripherally. In the last years several molecules, able to interact with KOR, have been the focus of basic research for their therapeutic potential in the field of chronic pain, as well as in depression, autoimmune disorders and neurological diseases. Topic The role of KOR system and the consequent clinical effects derived by its activation or inhibition are… 
Opioids in cancer: The κ-opioid receptor
Improved understanding of KOR may facilitate development of novel antitumor therapies and provide a novel basis for molecular targeted therapies for cancer.
The Potential Role of Dual Mechanistic Opioids in Combating Opioid Misuse
The aim of this review was to examine the value of so-called dual opioids, including tramadol and tapentadol, in this context to find a proper balance that meets the patient’s need for pain relief while minimizing abuse.
Alternative Splicing of Opioid Receptor Genes Shows a Conserved Pattern for 6TM Receptor Variants
It is discovered that N-terminally truncated 6 TM GPCRs are rare in the human genome and OPRs are overrepresented in this group and a significant enrichment of 6TM GPCR genes among genes associated with pain, psychiatric disorders, and addiction is observed.
Advances in Sulfonamide Kappa Opioid Receptor Antagonists: Structural Refinement and Evaluation of CNS Clearance.
Focused modification of a sulfonamide-based kappa opioid receptor (KOR) antagonist series previously reported by this laboratory was investigated and was found to attain suitable brain levels and to possess a shorter clearance time than canonical KOR antagonists such as JDTic.


Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development
This review will focus on possible therapeutic applications of ligand for KOR and specifically on the potential development of peptide ligands for these receptors.
Development of κ opioid receptor antagonists.
The preclinical research conducted in the development of several different classes of selective KOR antagonists are described, a summary of the clinical studies conducted thus far, and recommendations for the type of work needed in the future to determine if these agents would be useful as pharmacotherapies for neuropsychiatric illness are provided.
The Kappa Opioid Receptor: From Addiction to Depression, and Back
A large body of evidence from preclinical models indicating that the kappa opioid receptor (KOR), a member of the opioid neuromodulatory system, represents a central player in the regulation of both reward and mood processes is summarized.
Does the kappa opioid receptor system contribute to pain aversion?
Evidence is provided that dynorphin and the KOR system contribute to the negative affective component of pain and that this receptor system likely contributes to the high comorbidity of mood disorders associated with chronic neuropathic pain.
Targeting multiple opioid receptors – improved analgesics with reduced side effects?
The main focus of this review is to assess the paradigm of opioid ligands targeting multiple receptors with a single chemical entity and reflect on this rationale by discussing the biological actions of particular multi‐opioid receptor ligands, but not on their medicinal chemistry and design.
Delta and Kappa Opioid Receptors as Suitable Drug Targets for Pain
  • T. Vanderah
  • Biology, Medicine
    The Clinical journal of pain
  • 2010
New research has provided insight into why the development of effective κ and δ opioid receptor agonists has remained elusive thus far, and importantly, how these obstacles may be overcome.
Kappa Opioids, Salvinorin A and Major Depressive Disorder
It is concluded that salvinorin A has a complex pharmacologic profile, with potential additional mechanisms of action that make Salvinorina A an ideal candidate for MDD treatment research.
Peripherally restricted opioid agonists as novel analgesic agents.
This review focuses on a discussion of methods used to identify peripherally selective compounds, as well as a review of those compounds where sufficient data exist to support a claim of peripheralization in vivo.